MIP Pharma Danmark ApSAktiv
Økonomiske nøgletal
Nøgletal
2025/26Balancens sammensætning
Selskabsskat
indkomstår 2024Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk
Regnskabstal2018–2026
| 2017/18 | 2018/19 | 2019/20 | 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 | 2025/26 | |
|---|---|---|---|---|---|---|---|---|---|
| Balance — aktiver | |||||||||
| Likvide beholdninger | 10.764 | 17.524 | 15.928 | 21.147 | 24.600 | 20.462 | 29.565 | 19.124 | 15.075 |
| Omsætningsaktiver i alt | 10.764 | 17.524 | 15.928 | 22.007 | 24.600 | 21.637 | 38.363 | 31.253 | 27.619 |
| Anlægsaktiver i alt | — | — | — | — | — | — | — | — | — |
| Aktiver i alt | 10.764 | 17.524 | 15.928 | 22.007 | 24.600 | 21.637 | 38.363 | 31.253 | 27.619 |
| Balance — passiver | |||||||||
| Kortfristede gældsforpligtelser | 8.252 | 8.252 | 8.251 | 22.396 | 75.356 | 26.050 | 38.294 | 66.986 | 30.421 |
| Langfristede gældsforpligtelser | 186.311 | 226.441 | 262.781 | 307.396 | 336.095 | 447.490 | 561.107 | 680.950 | 687.193 |
| Gældsforpligtelser i alt | 194.563 | 234.693 | 271.032 | 329.792 | 411.451 | 473.540 | 599.401 | 747.936 | 717.614 |
| Selskabskapital | 80.011 | 80.011 | 80.011 | 80.011 | 80.011 | 80.011 | 80.011 | 80.011 | 80.011 |
| Overført resultat | -263.810 | -297.180 | -335.115 | -387.796 | -466.862 | -531.914 | -641.049 | -796.694 | -770.006 |
| Årets resultat | -34.986 | -33.370 | -37.935 | -52.682 | -79.066 | -65.052 | -109.135 | -155.646 | 26.688 |
| Egenkapital i alt | -183.799 | -217.169 | -255.104 | -307.785 | -386.851 | -451.903 | -561.038 | -716.683 | -689.995 |
| Resultatopgørelse | |||||||||
| Bruttofortjeneste | -26.573 | -23.103 | -24.001 | -38.537 | -48.214 | -38.668 | -92.378 | -129.052 | 57.700 |
| Resultat af primær drift | — | — | — | — | — | — | -92.378 | -129.052 | 57.700 |
| Resultat før skat | -34.986 | -33.370 | -37.935 | -52.682 | — | — | -109.135 | -155.646 | 26.688 |
| Årets resultat | -34.986 | -33.370 | -37.935 | -52.682 | -79.066 | -65.052 | -109.135 | -155.646 | 26.688 |
| Personaleomkostninger | — | — | — | — | — | — | 0 | 0 | 0 |
| Af- og nedskrivninger | — | — | — | — | — | — | — | — | — |
| Andre nøgletal | |||||||||
| Ansatte | 0 | 0 | 0 | — | — | — | — | 0 | 0 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2026Business reviewThe company's activities comprise the provision of services to its parent company in relation to the Danish market for pharmaceutical products..
Financial review The company's income statement for the year ended 30 June 2026 shows a profit of DKK 26,688, and the balance sheet at 30 June 2026 shows negative equity of DKK 689,995.At the end of the financial year, the company has lost all of its equity. As of 30 June 2026, the company's equity is negative by DKK 709,185. Management expects that the company will be able to restore its equity through its own operations. The company's parent company has issued a letter of support, which is valid until 1 January 2028, in order to enable MiP Pharma Danmark ApS to fulfil its obligations and pay its bills as they fall due.
Uddrag af ledelsesberetningen i den seneste årsrapport.